BioLineRx (BLRX) to Announce Earnings on Thursday

BioLineRx (NASDAQ:BLRX) is expected to issue its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect BioLineRx to announce earnings of ($0.15) per share and revenue of $0.50 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 21, 2026 at 6:46 AM ET.

BioLineRx (NASDAQ:BLRX) last announced its earnings results on Wednesday, May 27th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.04) by $0.68. BioLineRx had a negative return on equity of 37.73% and a negative net margin of 563.70%.The company had revenue of $0.48 million for the quarter, compared to analyst estimates of $0.34 million.

BioLineRx Trading Up 2.6%

BioLineRx stock opened at $2.78 on Wednesday. BioLineRx has a one year low of $2.15 and a one year high of $4.56. The stock has a market cap of $12.15 million, a PE ratio of -1.45 and a beta of 1.54. The company has a debt-to-equity ratio of 0.16, a quick ratio of 1.43 and a current ratio of 1.58. The stock has a 50-day moving average of $3.04 and a two-hundred day moving average of $2.86.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioLineRx in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

About BioLineRx

BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.

Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors.